healthcare.digital September 16, 2025
Executive Summary
The field of vagus nerve neuromodulation (VNN) is undergoing a profound transformation, moving beyond its established applications to emerge as a cornerstone of bioelectronic medicine. While vagus nerve stimulation (VNS) has long been a recognised treatment for refractory epilepsy and treatment-resistant depression, recent technological breakthroughs and landmark clinical trial results are expanding its therapeutic reach into a wide array of chronic inflammatory, neurological and psychiatric conditions. This report provides a detailed analysis of the VNN ecosystem, synthesising the foundational science, clinical evidence, market dynamics and critical regulatory and ethical considerations.
The market is characterised by a dual structure. One segment consists of established, highly regulated invasive medical devices, led by companies such as LivaNova, which continue to dominate...
Today's Sponsors
Today's Sponsor